Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Recent observations have suggested a role of neutrophil extracellular traps (NETs) in the pathophysiology of severe COVID-19. The aim of the study is to assess efficacy and safety of aerosolized DNase I to remove NETs and decrease respiratory distress in patients with COVID-19.
Description: Number of Days to cessation of oxygen therapy after start of treatment
Measure: Time to cessation of oxygen therapy DNase I to that of placebo (NaCl, 0.9%) on time to cessation of oxygen therapy hospitalized patients with COVID-19 and respiratory dysfunction. Time: 28 daysDescription: Number of diseased patients up to 28 Days after start of treatment
Measure: 28-day mortality Time: 28 daysDescription: Number of Days alive and without ventilator treatment up to 28 Days after start of treatment
Measure: Number of Days alive and without ventilator treatment Time: 28 daysDescription: Number of Days alive and without high flow nasal oxygen treatment (Optiflow) up to 28 Days after start of treatment
Measure: Number of Days alive and without high flow nasal oxygen treatment (Optiflow) Time: 28 daysDescription: Number of Days alive and free of stay in the ICU up to 28 Days after start of treatment
Measure: Number of Days alive and free of stay in the ICU Time: 28 daysDescription: Number of Days alive and outside hospital up to 28 Days after start of treatment
Measure: Number of Days alive and outside hospital Time: 28 daysDescription: Number of Days alive and free of a new episode and with oxygen saturation ≤93% after primary endpoint has been met up to 28 Days after start of treatment
Measure: Number of Days alive and free of a new episode and with oxygen saturation ≤93% after primary endpoint has been met Time: 28 daysDescription: Number of Days alive and without need of supplemental oxygen up to 28 Days after start of treatment
Measure: Number of Days alive and without need of supplemental oxygen Time: 28 daysDescription: Number of patients with adverse reactions reported up to 28 Days after start of treatment
Measure: Number of patients with adverse reactions Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports